Unità di Ricerca e di Malattie del sangue - Ematologia S. Luca Vecchio
Welcome,         Profile    Billing    Logout  
 7 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Santini, Valeria
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
FLO_CC-486-, NCT04806906: Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients

Active, not recruiting
2
11
Europe
CC-486, Oral Azacitidine
University of Florence
MDS, CMML
08/24
12/24
RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Recruiting
2
94
Europe, Canada
RVU120, SEL120
Ryvu Therapeutics SA
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome
02/26
09/26
Phoenix, NCT05924100 / 2021-001538-20: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Recruiting
2
22
Europe
Luspatercept Injection [Reblozyl]
Associazione Qol-one, Celgene BMS
Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia
12/24
12/29
REMARK_001, NCT06243458: RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Recruiting
2
41
Europe
RVU120 (SEL120)
GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group
Low Risk Myelodysplastic Syndromes
05/26
05/27
IDIOME-STUDY, NCT03503409: IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Active, not recruiting
2
68
Europe
AG-120
Groupe Francophone des Myelodysplasies
Myelodysplastic Syndromes, Acute Myeloid Leukemia
04/25
04/25
FISM_registry, NCT02808858: Italian Network MDS Registry

Recruiting
N/A
10000
Europe
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Myelodysplastic-Myeloproliferative Diseases
06/16
05/32
FISiM-Luspa, NCT05520749: Efficacy and Safety of Luspatercept: A Study by Fondazione Italiana Sindromi Mielodisplastiche

Completed
N/A
215
Europe
Luspatercept
Fondazione Italiana Sindromi Mielodisplastiche-ETS, Istituto Clinico Humanitas
Myeloid Dysplasia
12/22
01/23
NCT04587856: Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients

Recruiting
N/A
38
Europe
bone marrow withdrawal
Gruppo Italiano Malattie EMatologiche dell'Adulto
Myelodysplastic Syndromes
03/25
03/25
FISiM-NGS-MDS, NCT04212390: Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care

Recruiting
N/A
1000
Europe
Fondazione Italiana Sindromi Mielodisplastiche-ETS
MDS (Myelodysplastic Syndrome)
03/24
03/25

Download Options